A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Haematologica

Volumn 100, Issue 7, 2015, Pages 898-904

  Borthakur, Gautam ^a   Dombret, Herve ^b   Schafhausen, Philippe ^c   Brummendorf, Tim Henrik ^c,d   Boisse, Nicolas ^b   Jabbour, Elias ^a   Mariani, Mariangela ^e   Capolongo, Laura ^e   Carpinelli, Patrizia ^f   Davite, Cristina ^e   Kantarjian, Hagop ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Clinical Organization for Strategies and Solutions Srl(CLIOSS) Nerviano Medical Sciences   (Italy)

^f Nerviano Medical Sciences   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ASPARTATE AMINOTRANSFERASE; AURORA KINASE INHIBITOR; BARASERTIB; BOSUTINIB; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DANUSERTIB; DASATINIB; DOXORUBICIN; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; JANUS KINASE 2 INHIBITOR; MESNA; METHOTREXATE; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; VINCRISTINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; BULLOUS DERMATITIS; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOLYTIC HEPATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PNEUMONIA; STOMATITIS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VERY ELDERLY; BLAST CRISIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MIDDLE AGED; MUTATION; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLAST CRISIS; DRUG ADMINISTRATION SCHEDULE; FEBRILE NEUTROPENIA; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; MUCOSITIS; MUTATION; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84936127226     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115279     Document Type: Article

References (30)

1. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995;81(1):95-105.
2. Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 1999;9(11):454-459.
3. Barros TP, Kinoshita K, Hyman AA, Raff JW. Aurora A activates D-TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules. J Cell Biol. 2005;170(7):1039-1046.
4. Minoshima Y, Kawashima T, Hirose K, et al. Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis. Dev Cell. 2003;4(4):549-560.
5. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842-854.
6. Reiter R, Gais P, Jutting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(17):5136-5141.
7. Inamdar KV, O'Brien S, Sen S, et al. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol. 2008;21 (12):1428-1435.
8. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCRABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562-2569.
9. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
10. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA. 2002;99(16):10700-10705.
11. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276-283.
12. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088.
13. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005:183-187.
14. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007;6(12 Pt 1):3158-3168.
15. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008;111(8):4355-4364.
16. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 2007;67(17):7987-7990.
17. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009;27(30):5094-5101.
18. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res. 2009;15(21):6694-6701.
19. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002;22(3):874-885.
20. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6): 1809-1820.
21. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
22. Meulenbeld HJ, Bleuse JP, Vinci EM, et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int. 2013;111(1):44-52.
23. Fei F, Stoddart S, Groffen J, Heisterkamp N. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol Cancer Ther. 2010;9(5):1318-1327.
24. Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCRABL mutation. Blood. 2007;109(2):500-502.
25. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
26. Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573-2580.
27. Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with lowdose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013;13(5):559-567.
28. Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013;119(14): 2611-2619.
29. Benten D, Keller G, Quaas A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009;11(9):934-944.
30. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCRABL-positive cells in vitro. PLoS One. 2011;6(4):e19164.